Key result
Recent data suggest that the overall incidence of SARS-CoV-2-associated myocarditis is relatively low, yet infected individuals are at a substantially increased risk.
Why the study?
Knowledge regarding COVID-19-associated myocarditis continues to evolve rapidly, necessitating an update on its incidence, pathophysiology, diagnostic evaluation, and vaccine-related mechanisms.
The review summarizes recent data showing a relatively low overall incidence of COVID-19-associated myocarditis but a substantially increased risk among infected individuals, alongside updates on vaccine-associated myocarditis.
Heightened myocarditis risk in infected patients warrants clinical awareness despite low incidence; leaves open needs for mechanistic and prognostic studies.
The direct and indirect adverse effects of SARS-CoV-2 infection on the cardiovascular system, including myocarditis, are of paramount importance. These not only affect the disease course but also determine clinical outcomes and recovery. In this review, the authors aimed at providing an update on the incidence of Coronavirus disease-2019 (COVID-19)-associated myocarditis. Our knowledge and experience relevant to this area continues to evolve rapidly since the beginning of the pandemic. It is crucial for the scientific and medical community to stay abreast of current information. Contrasting early reports, recent data suggest that the overall incidence of SARS-CoV-2-associated myocarditis is relatively low, yet infected individuals are at a substantially increased risk. Therefore, understanding the pathophysiology and diagnostic evaluation, including the use of serum biomarkers and imaging modalities, remain important. This review aims to summarize the most recent data in these areas as they relate to COVID-19-associated myocarditis. Given its increasing relevance, a brief update is included on the proposed mechanisms of myocarditis in COVID-19 vaccine recipients.
No takes yet. Share an insight, caveat, or question.
Fraser et al. (2022) conducted a review in COVID-19-associated myocarditis. SARS-CoV-2 infection and COVID-19 vaccines was evaluated on Incidence of COVID-19-associated myocarditis. Recent data suggest that the overall incidence of SARS-CoV-2-associated myocarditis is relatively low, yet infected individuals are at a substantially increased risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: